Hanmi Pharmaceutical said on the 12th that it signed a co-promotion deal on the 7th with Korea Ferring Pharmaceuticals for the treatments for nocturia and nocturnal enuresis symptoms "Minirin tablet/Minirin Melt sublingual tablet" and the adult nocturia treatment "Nocturna sublingual tablet." Under the agreement, Hanmi Pharmaceutical will handle domestic distribution and supply of the products, while Korea Ferring Pharmaceuticals will be responsible for sales and marketing to general hospitals and Hanmi Pharmaceutical will focus on clinics and smaller hospitals.
In particular, Hanmi Pharmaceutical plans to focus sales on primary and secondary medical institutions, including small and midsize hospitals with 30 to 300 beds. The aim is to improve treatment access at points of care that nocturia patients most often visit.
Minirin is a therapy based on desmopressin, an ingredient similar to the antidiuretic hormone vasopressin. It reduces excessive nighttime urine production to ease frequent awakenings. It has been standardly used to treat primary nocturnal enuresis in children 5 and older, and is known to be effective for "nocturnal polyuria," which accounts for a substantial portion of adult nocturia cases.
Nocturna is an adult nocturia treatment developed as a low-dose version of Minirin. It is notable for lowering the risk of hyponatremia, a concern especially in older adults. As a sublingual tablet taken by dissolving under the tongue, it can be taken without water, improving dosing convenience.
Nocturia goes beyond a simple urination problem, degrading sleep quality and, especially among older adults, has been noted as a factor that increases the risk of falls during nighttime movement. Recently, interest has grown in treatments that balance safety with ease of administration.
Park Jae-hyun, CEO of Hanmi Pharmaceutical, said, "With this agreement, we can stably supply clinically validated nocturia treatments to Korea's medical field," adding, "We will strengthen collaboration with medical staff, focusing on clinics and smaller hospitals, to improve patients' access to treatment."
Kim Min-jung, CEO of Korea Ferring Pharmaceuticals, said, "As the number of patients experiencing discomfort from nocturia and nocturnal enuresis increases, demand is also growing for treatments that deliver both efficacy and safety," adding, "Through cooperation with Hanmi Pharmaceutical, we plan to supply related treatments more broadly."